Quantitative structure–pharmacokinetic/pharmacodynamic relationships
Quantitative structure–activity relationships have long been considered a vital component of drug discovery and development, providing insight into the role of molecular properties in the biological activity of similar and unrelated compounds. Recognition that in vitro bioassay and/or pre-clinical a...
Gespeichert in:
Veröffentlicht in: | Advanced drug delivery reviews 2006-11, Vol.58 (12), p.1326-1356 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1356 |
---|---|
container_issue | 12 |
container_start_page | 1326 |
container_title | Advanced drug delivery reviews |
container_volume | 58 |
creator | Mager, Donald E. |
description | Quantitative structure–activity relationships have long been considered a vital component of drug discovery and development, providing insight into the role of molecular properties in the biological activity of similar and unrelated compounds. Recognition that
in vitro bioassay and/or pre-clinical activity are insufficient for anticipating which compounds are suitable leads for further development has shifted the focus toward integrated pharmacokinetic (PK) and pharmacodynamic (PD) processes. Over the last decade, considerable progress has been made in constructing empirical and mechanistic quantitative structure–PK relationships (QSPKR), as well as diverse mechanism-based pharmacodynamic models of drug effects. In this review, traditional and contemporary approaches to developing QSPKR models are discussed, along with selected examples of attempts to couple QSPKR and pharmacodynamic models to anticipate the intensity and time-course of the pharmacological effects of new or related compounds, or quantitative structure–pharmacodynamic relationships modeling. Such models are in accordance with the goals of systems biology and the ideal of designing drugs and delivery systems from first principles. |
doi_str_mv | 10.1016/j.addr.2006.08.002 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68186391</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169409X06001670</els_id><sourcerecordid>20243276</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-1062d129b48cf1c21515459aabfc7e3f116506ae0fe83fd793e1ab9950430aa83</originalsourceid><addsrcrecordid>eNqFkcFq3DAURUVJaKZpf6CLkFV2dt6TbFmCbkpI2sJACKTQndDIz4ymY3siyQPZ5R_6h_mSaJgp2SWrx4Nz7-Iexr4ilAgoL1elbdtQcgBZgioB-Ac2Q9XwQnFdHbFZhnRRgf5zwj7FuAJA3kj4yE6wAc0lwIzd3E12SD7Z5Ld0HlOYXJoCPT_92yxt6K0b__qBkneX___2cbC9d-eB1jk0DnHpN_EzO-7sOtKXwz1lv2-u769-FvPbH7-uvs8LVymeCgTJW-R6USnXoeNYY13V2tpF5xoSHaKsQVqCjpTo2kYLQrvQuoZKgLVKnLKLfe8mjA8TxWR6Hx2t13agcYpGKlRSaHwXFAI56sy-B3LglcizZZDvQRfGGAN1ZhN8b8OjQTA7H2Zldj7MzocBZbKPHDo7tE-LntrXyEFABr7tAcqrbT0FE52nwVHrA7lk2tG_1f8CQ52dxg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20243276</pqid></control><display><type>article</type><title>Quantitative structure–pharmacokinetic/pharmacodynamic relationships</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Mager, Donald E.</creator><creatorcontrib>Mager, Donald E.</creatorcontrib><description>Quantitative structure–activity relationships have long been considered a vital component of drug discovery and development, providing insight into the role of molecular properties in the biological activity of similar and unrelated compounds. Recognition that
in vitro bioassay and/or pre-clinical activity are insufficient for anticipating which compounds are suitable leads for further development has shifted the focus toward integrated pharmacokinetic (PK) and pharmacodynamic (PD) processes. Over the last decade, considerable progress has been made in constructing empirical and mechanistic quantitative structure–PK relationships (QSPKR), as well as diverse mechanism-based pharmacodynamic models of drug effects. In this review, traditional and contemporary approaches to developing QSPKR models are discussed, along with selected examples of attempts to couple QSPKR and pharmacodynamic models to anticipate the intensity and time-course of the pharmacological effects of new or related compounds, or quantitative structure–pharmacodynamic relationships modeling. Such models are in accordance with the goals of systems biology and the ideal of designing drugs and delivery systems from first principles.</description><identifier>ISSN: 0169-409X</identifier><identifier>EISSN: 1872-8294</identifier><identifier>DOI: 10.1016/j.addr.2006.08.002</identifier><identifier>PMID: 17092600</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Absorption ; Area Under Curve ; Biological Availability ; Distribution ; Drug Delivery Systems - trends ; Excretion ; Humans ; Intestinal Absorption ; Metabolism ; Models, Biological ; Models, Molecular ; Molecular modeling ; Pharmacokinetic/pharmacodynamic modeling ; Pharmacokinetics ; Pharmacology ; Protein binding ; QSAR ; QSPR ; Structure-Activity Relationship</subject><ispartof>Advanced drug delivery reviews, 2006-11, Vol.58 (12), p.1326-1356</ispartof><rights>2006 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c482t-1062d129b48cf1c21515459aabfc7e3f116506ae0fe83fd793e1ab9950430aa83</citedby><cites>FETCH-LOGICAL-c482t-1062d129b48cf1c21515459aabfc7e3f116506ae0fe83fd793e1ab9950430aa83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.addr.2006.08.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17092600$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mager, Donald E.</creatorcontrib><title>Quantitative structure–pharmacokinetic/pharmacodynamic relationships</title><title>Advanced drug delivery reviews</title><addtitle>Adv Drug Deliv Rev</addtitle><description>Quantitative structure–activity relationships have long been considered a vital component of drug discovery and development, providing insight into the role of molecular properties in the biological activity of similar and unrelated compounds. Recognition that
in vitro bioassay and/or pre-clinical activity are insufficient for anticipating which compounds are suitable leads for further development has shifted the focus toward integrated pharmacokinetic (PK) and pharmacodynamic (PD) processes. Over the last decade, considerable progress has been made in constructing empirical and mechanistic quantitative structure–PK relationships (QSPKR), as well as diverse mechanism-based pharmacodynamic models of drug effects. In this review, traditional and contemporary approaches to developing QSPKR models are discussed, along with selected examples of attempts to couple QSPKR and pharmacodynamic models to anticipate the intensity and time-course of the pharmacological effects of new or related compounds, or quantitative structure–pharmacodynamic relationships modeling. Such models are in accordance with the goals of systems biology and the ideal of designing drugs and delivery systems from first principles.</description><subject>Absorption</subject><subject>Area Under Curve</subject><subject>Biological Availability</subject><subject>Distribution</subject><subject>Drug Delivery Systems - trends</subject><subject>Excretion</subject><subject>Humans</subject><subject>Intestinal Absorption</subject><subject>Metabolism</subject><subject>Models, Biological</subject><subject>Models, Molecular</subject><subject>Molecular modeling</subject><subject>Pharmacokinetic/pharmacodynamic modeling</subject><subject>Pharmacokinetics</subject><subject>Pharmacology</subject><subject>Protein binding</subject><subject>QSAR</subject><subject>QSPR</subject><subject>Structure-Activity Relationship</subject><issn>0169-409X</issn><issn>1872-8294</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFq3DAURUVJaKZpf6CLkFV2dt6TbFmCbkpI2sJACKTQndDIz4ymY3siyQPZ5R_6h_mSaJgp2SWrx4Nz7-Iexr4ilAgoL1elbdtQcgBZgioB-Ac2Q9XwQnFdHbFZhnRRgf5zwj7FuAJA3kj4yE6wAc0lwIzd3E12SD7Z5Ld0HlOYXJoCPT_92yxt6K0b__qBkneX___2cbC9d-eB1jk0DnHpN_EzO-7sOtKXwz1lv2-u769-FvPbH7-uvs8LVymeCgTJW-R6USnXoeNYY13V2tpF5xoSHaKsQVqCjpTo2kYLQrvQuoZKgLVKnLKLfe8mjA8TxWR6Hx2t13agcYpGKlRSaHwXFAI56sy-B3LglcizZZDvQRfGGAN1ZhN8b8OjQTA7H2Zldj7MzocBZbKPHDo7tE-LntrXyEFABr7tAcqrbT0FE52nwVHrA7lk2tG_1f8CQ52dxg</recordid><startdate>20061130</startdate><enddate>20061130</enddate><creator>Mager, Donald E.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7U5</scope><scope>L7M</scope><scope>7X8</scope></search><sort><creationdate>20061130</creationdate><title>Quantitative structure–pharmacokinetic/pharmacodynamic relationships</title><author>Mager, Donald E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-1062d129b48cf1c21515459aabfc7e3f116506ae0fe83fd793e1ab9950430aa83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Absorption</topic><topic>Area Under Curve</topic><topic>Biological Availability</topic><topic>Distribution</topic><topic>Drug Delivery Systems - trends</topic><topic>Excretion</topic><topic>Humans</topic><topic>Intestinal Absorption</topic><topic>Metabolism</topic><topic>Models, Biological</topic><topic>Models, Molecular</topic><topic>Molecular modeling</topic><topic>Pharmacokinetic/pharmacodynamic modeling</topic><topic>Pharmacokinetics</topic><topic>Pharmacology</topic><topic>Protein binding</topic><topic>QSAR</topic><topic>QSPR</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mager, Donald E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>MEDLINE - Academic</collection><jtitle>Advanced drug delivery reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mager, Donald E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quantitative structure–pharmacokinetic/pharmacodynamic relationships</atitle><jtitle>Advanced drug delivery reviews</jtitle><addtitle>Adv Drug Deliv Rev</addtitle><date>2006-11-30</date><risdate>2006</risdate><volume>58</volume><issue>12</issue><spage>1326</spage><epage>1356</epage><pages>1326-1356</pages><issn>0169-409X</issn><eissn>1872-8294</eissn><abstract>Quantitative structure–activity relationships have long been considered a vital component of drug discovery and development, providing insight into the role of molecular properties in the biological activity of similar and unrelated compounds. Recognition that
in vitro bioassay and/or pre-clinical activity are insufficient for anticipating which compounds are suitable leads for further development has shifted the focus toward integrated pharmacokinetic (PK) and pharmacodynamic (PD) processes. Over the last decade, considerable progress has been made in constructing empirical and mechanistic quantitative structure–PK relationships (QSPKR), as well as diverse mechanism-based pharmacodynamic models of drug effects. In this review, traditional and contemporary approaches to developing QSPKR models are discussed, along with selected examples of attempts to couple QSPKR and pharmacodynamic models to anticipate the intensity and time-course of the pharmacological effects of new or related compounds, or quantitative structure–pharmacodynamic relationships modeling. Such models are in accordance with the goals of systems biology and the ideal of designing drugs and delivery systems from first principles.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>17092600</pmid><doi>10.1016/j.addr.2006.08.002</doi><tpages>31</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0169-409X |
ispartof | Advanced drug delivery reviews, 2006-11, Vol.58 (12), p.1326-1356 |
issn | 0169-409X 1872-8294 |
language | eng |
recordid | cdi_proquest_miscellaneous_68186391 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Absorption Area Under Curve Biological Availability Distribution Drug Delivery Systems - trends Excretion Humans Intestinal Absorption Metabolism Models, Biological Models, Molecular Molecular modeling Pharmacokinetic/pharmacodynamic modeling Pharmacokinetics Pharmacology Protein binding QSAR QSPR Structure-Activity Relationship |
title | Quantitative structure–pharmacokinetic/pharmacodynamic relationships |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A36%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quantitative%20structure%E2%80%93pharmacokinetic/pharmacodynamic%20relationships&rft.jtitle=Advanced%20drug%20delivery%20reviews&rft.au=Mager,%20Donald%20E.&rft.date=2006-11-30&rft.volume=58&rft.issue=12&rft.spage=1326&rft.epage=1356&rft.pages=1326-1356&rft.issn=0169-409X&rft.eissn=1872-8294&rft_id=info:doi/10.1016/j.addr.2006.08.002&rft_dat=%3Cproquest_cross%3E20243276%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20243276&rft_id=info:pmid/17092600&rft_els_id=S0169409X06001670&rfr_iscdi=true |